SS-31 (Elamipretide) vs PE-22-28
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
SS-31 (Elamipretide)
SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.
Full details →PE-22-28
PE-22-28 is a synthetic peptide fragment derived from research on the SAMP8 mouse model of accelerated aging. It has shown potential for enhancing memory and reducing cognitive decline.
Full details →Side-by-Side Comparison
| Aspect | SS-31 (Elamipretide) | PE-22-28 |
|---|---|---|
| Mechanism | Concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency. | Derived from the protein that is deficient in SAMP8 mice. May work by inhibiting protein phosphatase 2A methylesterase, thereby affecting memory-related signaling pathways. |
| Typical Dosage | Clinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily. | Research protocols vary. Intranasal dosing has been studied at various concentrations. Optimal human dosing not established. |
| Administration | Can be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions. | Intranasal administration preferred for CNS delivery. Research compound with limited human use data. |
| Side Effects | Generally well-tolerated. Clinical trials reported injection site reactions and occasional headache. | Very limited human data. Primarily studied in animal models for safety and efficacy. |
| Best For |
What They Have in Common
Both SS-31 (Elamipretide) and PE-22-28 are commonly used for: